Erdafitinib (JNJ-42756493)

Erdafitinib (JNJ-42756493) is an inhibitor of FGFR and RET and related targets used in studies of MAPK / ERK Signaling and Immune Signaling and related signaling programs. In practice, this places the compound in experiments that measure mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and cytokine-mediated signaling and inflammatory effector responses in angiogenesis, apoptosis, and cancer models.

By inhibiting FGFR and RET and related targets, Erdafitinib (JNJ-42756493) can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and cytokine-mediated signaling and inflammatory effector responses. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In angiogenesis, apoptosis, and cancer models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving FGFR and RET and related targets
• Pathway perturbation studies connected to MAPK / ERK Signaling and Immune Signaling and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Erdafitinib (JNJ-42756493) is appropriate when a defined chemical perturbant is needed to connect FGFR and RET and related targets with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in angiogenesis, apoptosis, and cancer models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.